Dr. Reddy's Laboratories Limited

    Jurisdiction
    India
    LEI
    335800OVDPY3DVZR2798
    ISIN
    US2561352038 (RDY)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    trending_flat 48 / 100
    Even with peer group:
    49 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Dr. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €3.26B
    Gross margin
    57.7%
    EBIT
    €696.85M
    EBIT margin
    21.4%
    Net income
    €554.43M
    Net margin
    17.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €3.39B +4.0% €525.10M -5.3%
    €3.46B +2.1% €469.37M -10.6%
    €3.74B +7.9% €526.46M +12.2%

    Dividends

    Last dividend amount
    $0.09
    Ex date
    Payment date
    Dividend payout ratio
    11.7%

    Earnings Calls

    Latest earnings call: May 7, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 9.2M $121.29M -223K Sell

    Add to watchlist

    Notifications